Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0503 • ACR Convergence 2024
Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Patrick-Pascal Strunz¹, Linus Maximilian Risser², Matthias Englbrecht³, Torsten Witte⁴, Matthias Froehlich⁵, Marc Schmalzing⁶, Michael Gernert⁷, Peter Bartz-Bazzanella⁸, Sebastian Hueper⁹, Cay von Der Decken¹⁰, Georg Gauler¹¹, Susanna Spaethling-Mestekemper¹², Christoph Kuhn¹³, Kirsten Karberg¹⁴, Wolfgang Vorbrueggen¹⁵, Martin Welcker¹⁶ and Stefan Kleinert¹⁷, ¹University hospital of Wuerzburg, Wuerzburg, Germany, ²Hannover Medical School, Hannover, Germany, ³Freelance Healthcare Data Scientist, Eckental, ⁴Dept of Immunology and Rheumatology, Hannover, Germany, ⁵Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ⁶University Hospital Wuerzburg, Würzburg, Germany, ⁷Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ⁸Rhein-Maas Klinikum, Wuerselen, Germany, ⁹Praxis für Rheumatologie und Osteologie, Hildesheim, Germany, ¹⁰Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, ¹¹rheumapraxis, Osnabrück, Germany, ¹²Rheumapraxis Muenchen, Muenchen, Germany, ¹³Praxis für Rheumatologie, Karlsruhe, Germany, ¹⁴Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, ¹⁵RheumaDatenRhePort GbR, Wuerselen, Germany, ¹⁶Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ¹⁷Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence prescription patterns for drugs used…
Abstract Number: 0520 • ACR Convergence 2024
Disease Duration Differentially Affects the Clinical Efficacy of Biologics and JAK Inhibitors in Rheumatoid Arthritis: The ANSWER Cohort Study
Yoichi Nakayama¹, Daijiro Kabata², Wataru Yamamoto³, Hidehiko Makino⁴, Koji Nagai⁴, Naofumi Yoshida⁵, Yonsu Son⁵, Masaki Katayama⁶, Hirotaka Yamada⁷, Keisuke Nishimura⁷, Ryota Hara⁸, Ryu Watanabe⁹, Yuki Etani¹⁰, Kosuke Ebina¹¹, Hideo Onizawa¹², Takayuki Fujii¹³, Akira Onishi¹⁴, Kosaku Murakami¹⁵, Koichi Murata¹², Masao Tanaka¹⁴, Shuichi Matsuda¹², Akio Morinobu¹⁶, Ayumi Shintani² and Motomu Hashimoto⁹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Okayama, Japan, ⁴Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁵First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan, ⁶Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, ⁸Department of Orthopaedic Surgery, Nara Medical University, Nara, Nara, Japan, ⁹Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ¹⁰Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹¹Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ¹³Kyoto University, Kyoto, Japan, ¹⁴Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: A delay in initiating disease-modifying antirheumatic drugs (DMARDs) has been linked to poor outcomes in patients with rheumatoid arthritis (RA). Several studies have implicated…
Abstract Number: 0537 • ACR Convergence 2024
Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Knkush Hakobyan¹, Talar Acob², Mesrop Aleksanyan³, Tigran Kakhktsyan³, Omar Jumaah³ and Sajina Prabhakaran⁴, ¹Capital Health medical center, Princeton, NJ, ²College of medicine-university of Baghdad, Plainsboro Township, NJ, ³Capital Health Medical Center, Trenton, ⁴Capital health Rheumatology specialists, Newtown, PA
Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
Abstract Number: 0868 • ACR Convergence 2024
Autoantibodies to Joint-related Proteins Predict Severe Joint Destruction in Difficult-to-treat Rheumatoid Arthritis Patients
Inger Gjertsson¹, Monica Leu Agelii², Outi Sareila³, Erik Lönnblom⁴, Lennart TH Jacobsson⁵, Lei Cheng⁴, Kristina Forslind⁶, Ingiäld Hafström⁷, Maria Andersson⁸ and Rikard Holmdahl⁹, ¹University of Gothenburg, Gothenburg, Sweden, ²Institutionen för medicin, avd för reumatologi och inflammationsforskning, Goteborg, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Malmö, Sweden, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, ⁷Karolinska Institutet, Department of Medicine Huddinge, Division of Gastroenterology and Rheumatology, and Karolinska University Hospital, Stockholm, Sweden, ⁸FoU Spenshult, Halmstad, Sweden, ⁹Department of Rheumatology and Inflammation Research, Institute for Medicine, Sahlgrenska Academy, University of Gothenburg, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Although treatment of rheumatoid arthritis (RA) has improved there is still a significant number of patients who never reach low disease activity, known as…
Abstract Number: 0932 • ACR Convergence 2024
IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Grace Teng¹, Thomas Fung², Annamaria Mocciaro², Ceyda Llapashtica¹, Angie Hammond³, Jesse Gurgel⁴, zhiyu Huang¹, Maria Mouchess¹, Vanessa Gorney⁵, Wesley Minto¹, Sunish Mohanan¹, Adam Schrier¹, Wylie Palmer², Alexandra Borodovsky² and Gundula Min-oo¹, ¹Gilead Sciences, Foster City, CA, ²Nurix Therapeutics, San Francisco, CA, ³Gilead Sciences, Inc., Seattle, WA, ⁴Gilead Sciences, Seattle, CA, ⁵Alterome Therapeutics, San Diego, CA
Background/Purpose: Despite advances in treatment, chronic inflammatory diseases such as rheumatoid arthritis (RA) represent areas of high unmet medical need. IRAK4 is a proximal mediator…
Abstract Number: 0978 • ACR Convergence 2024
Associations of Fire Smoke and Other Pollutants with Incident Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Vanessa Kronzer¹, Yangyuna Yang², Punyasha Roul³, James Crooks⁴, Cynthia Crowson¹, John Davis¹, Jeffrey Sparks⁵, Jeffrey Pierce⁶, Katelyn O'Dell⁷, Sauer brian⁸, grant Cannon⁹, Joshua Baker¹⁰, Ted Mikuls² and Bryant England², ¹Mayo Clinic, Rochester, MN, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴National Jewish Health, Denver, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁶Colorado State University, Fort Collins, ⁷George Washington University, Washington DC, ⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁹University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁰Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

Background/Purpose: Wildfires have burned increasing acreage in the United States (US) since the 1980s, releasing record and alarming levels of particulate matter smaller than 2.5…
Abstract Number: 1036 • ACR Convergence 2024
A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care
Rosemary Gedert¹, Danielle Ochocki¹, Neda Kortam¹, Suiyuan Huang¹, Vivek Nagaraja², Katherine Chakrabarti¹, Julia Ford¹, Martin Garber¹, Jiha Lee¹, Vladimir Ognenovski¹, David Roofeh³, David Cella⁴ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Rutgers-RWJ Medical School, New Brunswick, NJ, ⁴Northwestern University, Chicago, IL
Background/Purpose: Utilizing Patient-Reported Outcomes Measurement Information System (PROMIS®) questionnaires can enhance clinical care by measuring longitudinal changes in symptom severity as reported by the patient.…
Abstract Number: 1228 • ACR Convergence 2024
Central Pain Mechanisms and Physical Function in Early Rheumatoid Arthritis
Burcu Aydemir¹, Lutfiyya Muhammad², Jing Song³, Dorothy Dunlop⁴, Kathleen Aren⁵, Mary Carns⁵, Wendy Marder⁶, Vivian Bykerk⁷, Kevin Deane⁸, Clifton Bingham⁹ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Worthington, MN, ⁴Northwestern University, New Haven, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶University of Michigan, Ann Arbor, MI, ⁷Hospital For Special Surgery, New York, NY, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹Johns Hopkins University, Baltimore, MD
Background/Purpose: Despite effective control of inflammation, patients with rheumatoid arthritis (RA) may experience lingering pain and losses in physical function. Pain can occur because central…
Abstract Number: 1335 • ACR Convergence 2024
The Association of Patient-Reported Non-Articular Pain with Musculoskeletal Pain Diagnoses and RA Disease Activity in a Prospective Real-World Cohort of Patients with Early RA
Charis Meng¹, Margaret Butler¹, Deanna Jannat-Khah¹, Yvonne Lee², Clifton Bingham³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University, Chicago, IL, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Non-articular pain (NAP) is often reported by early RA (eRA) patients, impacts RA remission (REM) but remains poorly defined and this hampers RA care.…
Abstract Number: 1351 • ACR Convergence 2024
Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements
Woo-Joong KIM¹, Chanseok PARK², Seungmo KOO², Jae-Young CHEONG² and Jiho KIM², ¹Chung-Ang University Hospital, Seoul, Korea, Seoul, Republic of Korea, ²Hongik University, Seoul, Korea, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires regular monitoring to prevent joint damage and systemic complications. However, the shortage of trained…
Abstract Number: 1367 • ACR Convergence 2024
Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
James Galloway¹, Jérôme Avouac², Gerd Burmester³, Roberto Caporali⁴, Thomas P.A. Debray⁵, Katrien Van Beneden⁶, Neil Betteridge⁷, Susana Romero Yuste⁸, Monia Zignani⁵, Patrick Verschueren⁹ and Karen Bevers¹⁰, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ³Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁵Alfasigma S.p.A., Bologna, Italy, ⁶Medical Affairs, Galapagos NV, Mechelen, Belgium, ⁷Neil Betteridge Associates, Lonodn, United Kingdom, ⁸Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁹Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ¹⁰Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients with RA. This interim analysis evaluated effectiveness and…
Abstract Number: 1384 • ACR Convergence 2024
Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Qianru Zhang¹, Gregory McDermott², Sung Hae Chang³, Pierre-Antoine Juge⁴, Kathleen Vanni⁵, Grace Qian⁶, Katarina Bade⁵, Kevin Mueller⁵, Emily Kowalski⁵, Alene Saavedra⁵ and Jeffrey Sparks⁷, ¹Harard Medical School, Cambridge, ²Brigham and Women's Hospital, Brookline, MA, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ⁴Service de Rhumatologie, Hôpital Bichat - Claude-Bernard, AP-HP, Paris, Île-de-France, France, PARIS, Germany, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a serious extra-articular manifestation of RA, affecting 7-12% of patients and associated with three-fold increased mortality compared to RA…
Abstract Number: 1400 • ACR Convergence 2024
Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer
Varun Nandakumar¹, Aaron Baraff², Alexander Peterson², Nicholas Smith³, Jennifer Barton⁴, Ann O'Hare², Christopher Li⁵, Noel Weiss³ and Namrata Singh⁶, ¹AIIMS, New Delhi, Delhi, India, ²VA PUGET SOUND SEATTLE, Seattle, WA, ³University of Washington, Seattle, WA, ⁴VA Portland Health Care System/OHSU, Portland, OR, ⁵University of Washington, Seattle, ⁶University of Washington, Bellevue, WA
Background/Purpose: Despite the significant therapeutic benefits of various disease modifying anti-rheumatic drugs (DMARDs) in RA, concerns remain regarding their safety, particularly their potential impact on…
Abstract Number: 1679 • ACR Convergence 2024
Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study
Nathanial Eddy¹, Jane Buckner², Paul Emery³, Michael Weinblatt⁴, Vivian Bykerk⁵, Andrew Cope⁶, Gerd Burmester⁷, Yoshiya Tanaka⁸, Gustavo Citera⁹, Peter Nash¹⁰, Quentin Dornic¹¹, Peter Schafer¹², Sheila Kelly¹³, Michael Maldonado¹¹ and Jinqi Liu¹¹, ¹Bristol Myers Squibb, Princeton, ²Benaroya Research Institute, Seattle, WA, ³University of Leeds, Leeds, United Kingdom, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Hospital For Special Surgery, New York, NY, ⁶King's College London, London, United Kingdom, ⁷Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ¹⁰Griffith University, Brisbane, Australia, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, BELLE MEAD, NJ, ¹³Bristol Myers Squibb, Doylestown, PA
Background/Purpose: Despite considerable advances in pharmacologic approaches to RA management, a better understanding of the underlying immunopathology is still needed.1,2 A dysregulated immune system is…
Abstract Number: 1836 • ACR Convergence 2024
Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint
Yang Yang¹, Yusuke Miyashita¹, Vitor Aguiar¹, Maria Gutierrez-Arcelus¹, Kellen Winden², Peter Nigrovic³ and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We previously…

« Previous Page
1
…
4
5
6
7
8
…
188
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].